442 related articles for article (PubMed ID: 14983408)
1. Effects of a combination of recombinant human growth hormone with metformin on glucose metabolism and body composition in patients with metabolic syndrome.
Herrmann BL; Berg C; Vogel E; Nowak T; Renzing-Koehler K; Mann K; Saller B
Horm Metab Res; 2004 Jan; 36(1):54-61. PubMed ID: 14983408
[TBL] [Abstract][Full Text] [Related]
2. Effects of a combination of rhGH and metformin on adiponectin levels in patients with metabolic syndrome.
Herrmann BL; Saller B; Stratmann M; Berg C; Mann K; Janssen OE
Horm Metab Res; 2005 Jan; 37(1):49-52. PubMed ID: 15702440
[TBL] [Abstract][Full Text] [Related]
3. Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients.
Nam SY; Kim KR; Cha BS; Song YD; Lim SK; Lee HC; Huh KB
Int J Obes Relat Metab Disord; 2001 Aug; 25(8):1101-7. PubMed ID: 11477493
[TBL] [Abstract][Full Text] [Related]
4. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure.
Johannsson G; Mårin P; Lönn L; Ottosson M; Stenlöf K; Björntorp P; Sjöström L; Bengtsson BA
J Clin Endocrinol Metab; 1997 Mar; 82(3):727-34. PubMed ID: 9062473
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R
Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
[TBL] [Abstract][Full Text] [Related]
6. [Effect of recombinant human growth hormone on glucose metabolism in children with growth hormone deficiency].
Liang L; Zou CC; Li Y; Wang CL; Jiang YJ; Dong GP; Fu JF; Wang XM
Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):657-61. PubMed ID: 17217656
[TBL] [Abstract][Full Text] [Related]
7. Growth hormone, insulin-like growth factors and their binding proteins in adult hemodialysis patients treated with recombinant human growth hormone.
Jensen PB; Hansen TB; Frystyk J; Ladefoged SD; Pedersen FB; Christiansen JS
Clin Nephrol; 1999 Aug; 52(2):103-9. PubMed ID: 10480221
[TBL] [Abstract][Full Text] [Related]
8. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
[TBL] [Abstract][Full Text] [Related]
9. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
10. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation.
Lo JC; Mulligan K; Noor MA; Schwarz JM; Halvorsen RA; Grunfeld C; Schambelan M
J Clin Endocrinol Metab; 2001 Aug; 86(8):3480-7. PubMed ID: 11502767
[TBL] [Abstract][Full Text] [Related]
11. Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial.
Franco C; Brandberg J; Lönn L; Andersson B; Bengtsson BA; Johannsson G
J Clin Endocrinol Metab; 2005 Mar; 90(3):1466-74. PubMed ID: 15598680
[TBL] [Abstract][Full Text] [Related]
12. The effect of 30 months of low-dose replacement therapy with recombinant human growth hormone (rhGH) on insulin and C-peptide kinetics, insulin secretion, insulin sensitivity, glucose effectiveness, and body composition in GH-deficient adults.
Rosenfalck AM; Maghsoudi S; Fisker S; Jørgensen JO; Christiansen JS; Hilsted J; Vølund AA; Madsbad S
J Clin Endocrinol Metab; 2000 Nov; 85(11):4173-81. PubMed ID: 11095450
[TBL] [Abstract][Full Text] [Related]
13. Low-dose recombinant human growth hormone as adjuvant therapy to lifestyle modifications in the management of obesity.
Albert SG; Mooradian AD
J Clin Endocrinol Metab; 2004 Feb; 89(2):695-701. PubMed ID: 14764783
[TBL] [Abstract][Full Text] [Related]
14. Defects of insulin action and skeletal muscle glucose metabolism in growth hormone-deficient adults persist after 24 months of recombinant human growth hormone therapy.
Christopher M; Hew FL; Oakley M; Rantzau C; Alford F
J Clin Endocrinol Metab; 1998 May; 83(5):1668-81. PubMed ID: 9589675
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial.
Glesby MJ; Albu J; Chiu YL; Ham K; Engelson E; He Q; Muthukrishnan V; Ginsberg HN; Donovan D; Ernst J; Lesser M; Kotler DP
PLoS One; 2013; 8(4):e61160. PubMed ID: 23593417
[TBL] [Abstract][Full Text] [Related]
16. Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study.
Florakis D; Hung V; Kaltsas G; Coyte D; Jenkins PJ; Chew SL; Grossman AB; Besser GM; Monson JP
Clin Endocrinol (Oxf); 2000 Oct; 53(4):453-9. PubMed ID: 11012570
[TBL] [Abstract][Full Text] [Related]
17. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.
Vittone J; Blackman MR; Busby-Whitehead J; Tsiao C; Stewart KJ; Tobin J; Stevens T; Bellantoni MF; Rogers MA; Baumann G; Roth J; Harman SM; Spencer RG
Metabolism; 1997 Jan; 46(1):89-96. PubMed ID: 9005976
[TBL] [Abstract][Full Text] [Related]
18. Metabolic effects of biosynthetic growth hormone treatment in severely energy-restricted obese women.
Tagliaferri M; Scacchi M; Pincelli AI; Berselli ME; Silvestri P; Montesano A; Ortolani S; Dubini A; Cavagnini F
Int J Obes Relat Metab Disord; 1998 Sep; 22(9):836-41. PubMed ID: 9756240
[TBL] [Abstract][Full Text] [Related]
19. Effects of short-term administration of low-dose rhGH on IGF-I levels in obesity and Cushing's syndrome: indirect evaluation of sensitivity to GH.
Maccario M; Tassone F; Gauna C; Oleandri SE; Aimaretti G; Procopio M; Grottoli S; Pflaum CD; Strasburger CJ; Ghigo E
Eur J Endocrinol; 2001 Mar; 144(3):251-6. PubMed ID: 11248744
[TBL] [Abstract][Full Text] [Related]
20. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
Rosenstock J; Rood J; Cobitz A; Biswas N; Chou H; Garber A
Diabetes Obes Metab; 2006 Nov; 8(6):650-60. PubMed ID: 17026489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
